This study tests an oral drug called APG-157 given before standard treatment (surgery or radiation) for people with newly diagnosed head and neck cancer. The goal is to see if the drug can shrink tumors and improve outcomes. About 24 adults with early to advanced stage cancer wil…
Phase: PHASE2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC